Literature DB >> 23115130

Common variation in the LRRK2 gene is a risk factor for Parkinson's disease.

Ignacio F Mata1, Harvey Checkoway, Carolyn M Hutter, Ali Samii, John W Roberts, Hojoong M Kim, Pinky Agarwal, Victoria Alvarez, Renee Ribacoba, Pau Pastor, Oswaldo Lorenzo-Betancor, Jon Infante, María Sierra, Pilar Gómez-Garre, Pablo Mir, Beate Ritz, Shannon L Rhodes, Amy Colcher, Vivianna Van Deerlin, Kathryn A Chung, Joseph F Quinn, Dora Yearout, Erica Martinez, Federico M Farin, Jia Y Wan, Karen L Edwards, Cyrus P Zabetian.   

Abstract

BACKGROUND: Common variants in the LRRK2 gene influence the risk of Parkinson's disease (PD) in Asians, but whether the same is true in European-derived populations is less clear.
METHODS: We genotyped 66 LRRK2 tagging single-nucleotide polymorphisms (SNPs) in 575 PD patients and 689 controls from the northwestern United States (tier 1). PD-associated SNPs (P < .05) were then genotyped in an independent sample of 3617 cases and 2512 controls from the United States and Spain (tier 2). Logistic regression was used to model additive SNP genotype effects adjusted for age and sex among white individuals.
RESULTS: Two regions showed independent association with PD in tier 1, and SNPs in both regions were successfully replicated in tier 2 (rs10878226, combined odds ratio [OR], 1.20; 95% confidence interval [CI], 1.08-1.33; P = 6.3 × 10(-4); rs11176013, OR, 0.89; CI, 0.83-0.95; P = 4.6 × 10(-4)).
CONCLUSIONS: Our data suggest that common variation within LRRK2 conveys susceptibility for PD in individuals of European ancestry.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23115130      PMCID: PMC3536918          DOI: 10.1002/mds.25226

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  20 in total

1.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

2.  A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations.

Authors:  C P Zabetian; A Samii; A D Mosley; J W Roberts; B C Leis; D Yearout; W H Raskind; A Griffith
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

3.  Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls.

Authors:  Coro Paisán-Ruíz; Priti Nath; Nicole Washecka; J Raphael Gibbs; Andrew B Singleton
Journal:  Hum Mutat       Date:  2008-04       Impact factor: 4.878

4.  Common variants of LRRK2 are not associated with sporadic Parkinson's disease.

Authors:  Saskia Biskup; Jakob C Mueller; Manu Sharma; Peter Lichtner; Alexander Zimprich; Daniela Berg; Ullrich Wüllner; Thomas Illig; Thomas Meitinger; Thomas Gasser
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

5.  Clinical characteristics in early Parkinson's disease in a central California population-based study.

Authors:  Gail A Kang; Jeff M Bronstein; Donna L Masterman; Matthew Redelings; Jarrod A Crum; Beate Ritz
Journal:  Mov Disord       Date:  2005-09       Impact factor: 10.338

Review 6.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

7.  Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake.

Authors:  Harvey Checkoway; Karen Powers; Terri Smith-Weller; Gary M Franklin; W T Longstreth; Phillip D Swanson
Journal:  Am J Epidemiol       Date:  2002-04-15       Impact factor: 4.897

8.  Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease.

Authors:  Owen A Ross; Yih-Ru Wu; Mei-Ching Lee; Manabu Funayama; Meng-Ling Chen; Alexandra I Soto; Ignacio F Mata; Guey-Jen Lee-Chen; Chiung Mei Chen; Michelle Tang; Yi Zhao; Nobutaka Hattori; Matthew J Farrer; Eng-King Tan; Ruey-Meei Wu
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

9.  LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease.

Authors:  Cyrus P Zabetian; Mitsutoshi Yamamoto; Alexis N Lopez; Hiroshi Ujike; Ignacio F Mata; Yuishin Izumi; Ryuji Kaji; Hirofumi Maruyama; Hiroyuki Morino; Masaya Oda; Carolyn M Hutter; Karen L Edwards; Gerard D Schellenberg; Debby W Tsuang; Dora Yearout; Eric B Larson; Hideshi Kawakami
Journal:  Mov Disord       Date:  2009-05-15       Impact factor: 10.338

10.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.

Authors:  Javier Simón-Sánchez; Claudia Schulte; Jose M Bras; Manu Sharma; J Raphael Gibbs; Daniela Berg; Coro Paisan-Ruiz; Peter Lichtner; Sonja W Scholz; Dena G Hernandez; Rejko Krüger; Monica Federoff; Christine Klein; Alison Goate; Joel Perlmutter; Michael Bonin; Michael A Nalls; Thomas Illig; Christian Gieger; Henry Houlden; Michael Steffens; Michael S Okun; Brad A Racette; Mark R Cookson; Kelly D Foote; Hubert H Fernandez; Bryan J Traynor; Stefan Schreiber; Sampath Arepalli; Ryan Zonozi; Katrina Gwinn; Marcel van der Brug; Grisel Lopez; Stephen J Chanock; Arthur Schatzkin; Yikyung Park; Albert Hollenbeck; Jianjun Gao; Xuemei Huang; Nick W Wood; Delia Lorenz; Günther Deuschl; Honglei Chen; Olaf Riess; John A Hardy; Andrew B Singleton; Thomas Gasser
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

View more
  8 in total

Review 1.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

Review 2.  LRRK2 and Proteostasis in Parkinson's Disease.

Authors:  María Dolores Pérez-Carrión; Inmaculada Posadas; Javier Solera; Valentín Ceña
Journal:  Int J Mol Sci       Date:  2022-06-18       Impact factor: 6.208

3.  Fine-mapping of Parkinson's disease susceptibility loci identifies putative causal variants.

Authors:  Brian M Schilder; Towfique Raj
Journal:  Hum Mol Genet       Date:  2022-03-21       Impact factor: 5.121

4.  Understanding the role of genetic variability in LRRK2 in Indian population.

Authors:  Asha Kishore; Ashwin Ashok Kumar Sreelatha; Marc Sturm; Felix von-Zweydorf; Lasse Pihlstrøm; Francesco Raimondi; Rob Russell; Peter Lichtner; Moinak Banerjee; Syam Krishnan; Roopa Rajan; Divya Kalikavil Puthenveedu; Sun Ju Chung; Peter Bauer; Olaf Riess; Christian Johannes Gloeckner; Rejko Kruger; Thomas Gasser; Manu Sharma
Journal:  Mov Disord       Date:  2018-11-28       Impact factor: 10.338

Review 5.  Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration.

Authors:  Carla Ribeiro Alvares Batista; Giovanni Freitas Gomes; Eduardo Candelario-Jalil; Bernd L Fiebich; Antonio Carlos Pinheiro de Oliveira
Journal:  Int J Mol Sci       Date:  2019-05-09       Impact factor: 5.923

6.  Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.

Authors:  Kenneth Thirstrup; Justus C Dächsel; Felix S Oppermann; Douglas S Williamson; Garrick P Smith; Karina Fog; Kenneth V Christensen
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

7.  Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson's Disease Progression.

Authors:  Selma Yılmazer; Esin Candaş; Gençer Genç; Merve Alaylıoğlu; Büşra Şengül; Ayşegül Gündüz; Hülya Apaydın; Güneş Kızıltan; Sibel Ertan; Erdinç Dursun; Duygu Gezen-Ak
Journal:  Neuromolecular Med       Date:  2020-10-04       Impact factor: 3.843

8.  Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease.

Authors:  Emmeline E Brown; Cornelis Blauwendraat; Joanne Trinh; Mie Rizig; Mike A Nalls; Etienne Leveille; Jennifer A Ruskey; Hallgeir Jonvik; Manuela M X Tan; Sara Bandres-Ciga; Sharon Hassin-Baer; Kathrin Brockmann; Jon Infante; Eduardo Tolosa; Mario Ezquerra; Sawssan Ben Romdhan; Mustapha Benmahdjoub; Mohamed Arezki; Chokri Mhiri; John Hardy; Andrew B Singleton; Roy N Alcalay; Thomas Gasser; Donald G Grosset; Nigel M Williams; Alan Pittman; Ziv Gan-Or; Ruben Fernandez-Santiago; Alexis Brice; Suzanne Lesage; Matthew Farrer; Nicholas Wood; Huw R Morris
Journal:  Neurobiol Aging       Date:  2020-07-13       Impact factor: 4.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.